X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AJANTA PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AJANTA PHARMA FRESENIUS KABI ONCO./
AJANTA PHARMA
 
P/E (TTM) x 22.1 28.6 77.5% View Chart
P/BV x 3.1 11.8 26.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   AJANTA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA
Mar-16
FRESENIUS KABI ONCO./
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,720 10.2%   
Low Rs791,103 7.1%   
Sales per share (Unadj.) Rs37.7194.6 19.4%  
Earnings per share (Unadj.) Rs5.145.2 11.3%  
Cash flow per share (Unadj.) Rs6.750.3 13.4%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs42.5132.0 32.2%  
Shares outstanding (eoy) m158.2388.77 178.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.3 46.6%   
Avg P/E ratio x25.031.2 80.0%  
P/CF ratio (eoy) x18.928.1 67.4%  
Price / Book Value ratio x3.010.7 28.0%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m20,135125,299 16.1%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7032,570 27.4%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96317,275 34.5%  
Other income Rs m18166 10.8%   
Total revenues Rs m5,98117,442 34.3%   
Gross profit Rs m1,4305,807 24.6%  
Depreciation Rs m258451 57.2%   
Interest Rs m-2649 -53.2%   
Profit before tax Rs m1,2165,474 22.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,460 23.4%   
Profit after tax Rs m8064,014 20.1%  
Gross profit margin %24.033.6 71.3%  
Effective tax rate %28.126.7 105.5%   
Net profit margin %13.523.2 58.2%  
BALANCE SHEET DATA
Current assets Rs m5,1027,639 66.8%   
Current liabilities Rs m2,3852,715 87.9%   
Net working cap to sales %45.628.5 159.8%  
Current ratio x2.12.8 76.0%  
Inventory Days Days15043 347.1%  
Debtors Days Days11379 144.0%  
Net fixed assets Rs m5,1486,914 74.5%   
Share capital Rs m158177 89.4%   
"Free" reserves Rs m6,55611,442 57.3%   
Net worth Rs m6,73211,721 57.4%   
Long term debt Rs m952149 640.3%   
Total assets Rs m10,38814,814 70.1%  
Interest coverage x-45.8112.9 -40.5%   
Debt to equity ratio x0.10 1,114.9%  
Sales to assets ratio x0.61.2 49.2%   
Return on assets %7.527.4 27.4%  
Return on equity %12.034.2 35.0%  
Return on capital %14.646.5 31.4%  
Exports to sales %74.555.1 135.0%   
Imports to sales %24.86.0 412.5%   
Exports (fob) Rs m4,4419,527 46.6%   
Imports (cif) Rs m1,4771,038 142.4%   
Fx inflow Rs m5,29810,422 50.8%   
Fx outflow Rs m1,7721,678 105.6%   
Net fx Rs m3,5258,744 40.3%   
CASH FLOW
From Operations Rs m1,2743,264 39.0%  
From Investments Rs m-1,204-2,093 57.5%  
From Financial Activity Rs m-196-1,186 16.5%  
Net Cashflow Rs m-126-15 853.4%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 9.6 7.6 126.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   42,599 20,968 203.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PANACEA BIOTECH  ALEMBIC PHARMA  GLENMARK PHARMA  GSK PHARMA  DR. DATSONS LABS  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS